Semaglutide Use in Elderly Obese Patients
- Status
- CompletedResults posted
- Why it is watched
- non-weight indication: lean_mass, aging
- Who it enrolls
- age 65 Years to no upper limit; healthy volunteers accepted; excludes diabetes; BMI ≥30 required; non-obese participants included; conditions: Obesity; Aging
- Interventions
- Semaglutide Pen Injector
- Conditions
- Obesity; Aging
- Phase and size
- Phase 2 · 16 participants
- Dates
- Start 2022-09-01
Primary completion 2023-10-23 - Sponsor
- State University of New York at Buffalo (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Body Composition as Total Fat Mass/ Total Fat-free Mass Ratio16 weeks
- Body Weight16 weeks
02Eligibility
Who can take part
Inclusion Criteria: 1. Males and females age: ≥65 years 2. BMI ≥30 Kg/m2 AND waist circumference for women: \> 80 cm and for men: \> 90 cm 3. Stable body weight (no more than ±3 kg change during the 3 months prior to screening) 4. Able to participate in personalized physical activities and dietary instructions. 5. Participant must be able to read, write, and understand the English language and be able to provide written consent. Exclusion Criteria: 1. Current diagnosis of weight changing condition including cancer, gastrointestinal conditions or eating disorders 2. GLP-1R agonists use within last 6 months 3. Diagnosis of type 1 or 2 diabetes 4. Impaired cognitive function (VA-St. Louis University Mental Survey (VA-SLUMS) score ≤ 19) 5. History of chronic/idiopathic acute pancreatitis 6. Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 7. Previous surgical treatment for obesity 8. Smoking or use of any nicotine products 9. Use of any medication that could interfere with trial results especially weight management drugs 10. Anticipated change in lifestyle (e.g., dietary, exercise or sleeping pattern) other than provided by the study. 11. Hepatic disease or cirrhosis 12. Aspartate Aminotransferase (AST) \> 3X Upper limit of normal (ULN) and/or Alanine aminotransferase (ALT) \> 3X ULN 13. Inability to give informed consent 14. History of gastroparesis 15. History of serious hypersensitivity reaction to these agents 16. Alcoholism 17. Patients with retinopathy 18. Participation in any other concurrent interventional clinical trial -
03Change log
Registry changes
No changes recorded since the trial was added.